Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lestaurtinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 known ✓ | P04629 | 10/20 | 1.00 |
| ▸ | FLT3 known ✓ | P36888 | 5/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 2/20 | 1.00 |
| ▸ | RET known ✓ | P07949 | 2/20 | 1.00 |
| ▸ | NTRK3 known ✓ | Q16288 | 1/20 | 1.00 |
| ▸ | NTRK2 known ✓ | Q16620 | 1/20 | 1.00 |
| ▸ | KDR | P35968 | 9/20 | 1.00 |
| ▸ | PRKCQ | Q04759 | 7/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCH | P24723 | 5/20 | 1.00 |
| ▸ | PRKCI | P41743 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 5/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 5/20 | 1.00 |
| ▸ | PRKD1 | Q15139 | 5/20 | 1.00 |
| ▸ | MYLK | Q15746 | 4/20 | 1.00 |
| ▸ | CDK4 | P11802 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | MAP3K11 | Q16584 | 3/20 | 1.00 |
| ▸ | CAMKK2 | Q96RR4 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lestaurtinib SCHEMBL16139562 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL730955 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL1649693 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL12228516 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL29625224 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL17971367 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL17971365 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL13169434 | 1.00 | NTRK1 (1.00) | NTRK1KDRPRKCQFLT3PRKD3 | |
| Lestaurtinib SCHEMBL30149252 | 0.99 | NTRK1 (0.98) | NTRK1KDRPRKCQFLT3PRKD3 | |
| SCHEMBL14342269 | 0.94 | NTRK1 (0.89) | NTRK1KDRPRKCQFLT3PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 5259 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137953-A1 | METHOD FOR TARGETED TREATING DERMATOSES | STRATA SKIN SCIENCES INC. (US) | 2026-05-21 | — | — | US | claimed |
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026090557-A1 | SYSTEMS AND METHODS FOR PROCESSING ISM AND MCAS CLINICAL TRIAL DATA | TELIOS PHARMA INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4731220-A2 | METHODS OF TREATING CHRONIC LYMPHOCYTIC LEUKEMIA | Dana Farber Cancer Institute, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12611408-B2 | Methods for treating nail brittleness, fragility, or pitting | CHEMISTRY RX (US) | 2026-04-28 | — | — | US | claimed |
| EP-4719499-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF CD33-POSITIVE HEMATOLOGICAL MALIGNANCIES HARBORING MUTATIONS | Actinium Pharmaceuticals, Inc. (US) | 2026-04-08 | — | — | EP | claimed |
| EP-4722388-A1 | PREDICTION OF AN OUTCOME OF A SUBJECT SUFFERING FROM ACUTE MYOLOID LEUKEMIA | Koninklijke Philips N.V. (NL) | 2026-04-08 | — | — | EP | claimed |
| US-20260085061-A1 | PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS | SITRYX THERAPEUTICS LIMITED (GB) | 2026-03-26 | — | — | US | claimed |
| US-20220105026-A1 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A JAK INHIBITOR AND DEVICES | GLAS USA LLC | 2022-04-07 | — | — | US | claimed |
| US-20220105097-A1 | METHODS OF TREATMENT OF MYELOPROLIFERATIVE NEOPLASM | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-04-07 | — | — | US | claimed |
| WO-2022072238-A1 | TARGETING POLYCYTHEMIA VERA (PV)-INITIATING CELLS BY BLOCKING LEUKOTRIENE BINDING TO THEIR RECEPTORS | UNIVERSITY OF MASSACHUSETTS (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3962559-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | University of Houston System (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3955920-A1 | USE OF JAK INHIBITORS FOR THE TREATMENT OF PAINFUL CONDITIONS INVOLVING NAV1.7 CHANNELS | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2022-02-23 | — | — | EP | claimed |
| US-20220040185-A1 | USE OF TREM-1 INHIBITORS FOR TREATMENT, ELIMINATION AND ERADICATION OF HIV-1 INFECTION | UNIV EMORY (US) | 2022-02-10 | — | — | US | claimed |
| WO-2022023490-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) | 2022-02-03 | — | — | WO | claimed |
| EP-3944859-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | Assistance Publique Hôpitaux de Paris (FR) | 2022-02-02 | — | — | EP | claimed |
| CN-114007671-A | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia and cancer of epithelial tissue | 休斯敦大学体系 | 2022-02-01 | — | — | CN | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |